Recent News

• 09.12.2025 - Gelteq Technology Powers U.S. Product Launches of its Nutraceutical Products for Partner
• 09.05.2025 - Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market
• 06.10.2025 - Gelteq Expands U.S. Operations with Healthy Extracts Inc. as North American Fulfillment Partner
• 02.27.2025 - Gelteq’s Sportsgel Brand Named Official Sponsor of the Professional Pickleball Tour and League of Australia and New Zealand
• 02.04.2025 - Gelteq Launches SportsGel Brand and Signs Distribution Agreement with E-Commerce Solutions Company in Asia-Pacific Region, WPIC
• 01.24.2025 - Gelteq Appoints Matthew Jones as Head of Sports Performance
• 12.19.2024 - Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology
• 12.17.2024 - Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug
• 12.17.2024 - Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug
• 12.09.2024 - Gelteq to Participate in the Benchmark Company 13th Annual Discovery Investor Conference

Recent Filings

• 08.29.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 08.29.2025 - EFFECT Notice of Effectiveness
• 07.25.2025 - F-1/A Registration statement for certain foreign private issuers
• 07.01.2025 - F-1 Registration statement for certain foreign private issuers
• 06.30.2025 - EX-99.1 EX-99.1
• 06.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]